Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKBANASDAQ:ALDROTCMKTS:BLUSFNASDAQ:CNSTOTCMKTS:CYDY Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.37+0.7%$1.59$0.65▼$2.48$286.84M0.794.32 million shs2.09 million shsALDRAlder Biopharmaceuticals$18.88$18.88$8.39▼$19.12$1.58B2.645.12 million shsN/ABLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsCNSTConstellation Pharmaceuticals$33.99$33.89$17.00▼$39.30$1.63B2.59940,325 shsN/ACYDYCytoDyn$0.15$0.17$0.13▼$0.42$148.93M0.172.69 million shs423,580 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-2.16%-37.33%-2.86%+106.03%ALDRAlder Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%BLUSFBELLUS Health0.00%0.00%0.00%0.00%+2.15%CNSTConstellation Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CYDYCytoDyn-3.16%+3.52%-8.14%-8.98%-50.63%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics3.4243 of 5 stars3.52.00.04.01.10.80.6ALDRAlder BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/ACNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics3.00Buy$5.00264.96% UpsideALDRAlder BiopharmaceuticalsN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/ACNSTConstellation PharmaceuticalsN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/ACurrent Analyst RatingsLatest ALDR, CYDY, AKBA, CNST, and BLUSF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.003/15/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$194.62M1.47N/AN/A($0.16) per share-8.56ALDRAlder Biopharmaceuticals$1.62M977.10N/AN/A$1.61 per share11.73BLUSFBELLUS Health$30K0.00N/AN/A$0.25 per share0.00CNSTConstellation PharmaceuticalsN/AN/AN/AN/A$8.63 per shareN/ACYDYCytoDyn$270K551.59N/AN/A($0.12) per share-1.25Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.28N/AN/AN/A-26.32%N/A-20.36%5/13/2024 (Estimated)ALDRAlder Biopharmaceuticals-$296.43M-$4.87N/AN/AN/AN/A-226.13%-66.86%N/ABLUSFBELLUS Health-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/ACNSTConstellation Pharmaceuticals-$126.36M-$2.81N/AN/AN/AN/A-33.12%-29.92%N/ACYDYCytoDyn-$79.82M-$0.05N/A∞N/AN/AN/A-478.47%N/ALatest ALDR, CYDY, AKBA, CNST, and BLUSF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/15/2024Q3 2024CYDYCytoDynN/A-$0.01-$0.01-$0.01N/AN/A3/14/2024Q4 2023AKBAAkebia Therapeutics-$0.04-$0.04N/AN/A$55.64 million$56.20 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AALDRAlder BiopharmaceuticalsN/AN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/AN/ACNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.181.03ALDRAlder Biopharmaceuticals1.748.948.94BLUSFBELLUS HealthN/A13.8713.87CNSTConstellation PharmaceuticalsN/A15.3915.39CYDYCytoDynN/A0.080.08OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%ALDRAlder BiopharmaceuticalsN/ABLUSFBELLUS HealthN/ACNSTConstellation PharmaceuticalsN/ACYDYCytoDyn5.06%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.84%ALDRAlder Biopharmaceuticals15.40%BLUSFBELLUS Health24.17%CNSTConstellation Pharmaceuticals43.70%CYDYCytoDyn0.71%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics167209.37 million201.33 millionOptionableALDRAlder Biopharmaceuticals20283.84 millionN/AOptionableBLUSFBELLUS Health10159.12 millionN/ANot OptionableCNSTConstellation Pharmaceuticals15447.92 millionN/ANot OptionableCYDYCytoDyn12992.87 million985.82 millionNot OptionableALDR, CYDY, AKBA, CNST, and BLUSF HeadlinesSourceHeadlineCytoDyn Inc. (OTCMKTS:CYDY) Short Interest Updatemarketbeat.com - April 15 at 11:14 PMFinancial Contrast: Societal CDMO (NASDAQ:SCTL) & CytoDyn (OTCMKTS:CYDY)americanbankingnews.com - April 15 at 1:28 AMCytoDyn finally clears FDA hold on HIV program after two yearsfiercebiotech.com - February 29 at 1:22 PMCytoDyn Says FDA Lifts Hold On Leronlimabmarkets.businessinsider.com - February 29 at 1:22 PMFDA lifts clinical hold on CytoDyn drug, stock rallies 22%msn.com - February 29 at 1:22 PMCytoDyn Announces FDA Has Lifted Clinical Holdglobenewswire.com - February 29 at 8:30 AMCytoDyn Inc CYDYmorningstar.com - February 10 at 2:26 AMVancouver biotechnology company CytoDyn faces another lawsuitcolumbian.com - February 2 at 9:38 AMCytoDyn Submits Revised HIV Clinical Trial Protocol To FDA, Starts Glioblastoma Pre-Clinical Studymarkets.businessinsider.com - February 1 at 2:24 PMCytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastomafinance.yahoo.com - February 1 at 2:24 PMCytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastomatmcnet.com - February 1 at 9:23 AMInvestors file another lawsuit against CytoDynbizjournals.com - January 31 at 7:26 PMCytoDyn Leaders Hit With Insider Trading Claims Over HIV Drugnews.bloomberglaw.com - January 31 at 9:26 AMCytoDyn Releases Regulatory FD Disclosure Informationmsn.com - January 30 at 6:24 PMCytoDyn Announces Executive Leadership Changes and Appointmentsmsn.com - January 30 at 8:32 AMVancouver biotech appoints new CEO, as former top executive awaits fraud trialbizjournals.com - January 29 at 8:01 PMCytoDyn Inc.: CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFOfinanznachrichten.de - January 29 at 3:01 PMCytoDyn appoints Jacob Lalezari as CEO, Mitchell Cohen as interim CFOmsn.com - January 29 at 10:00 AMCytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFOfinance.yahoo.com - January 29 at 10:00 AMCytoDyn Announces Webcast to Provide Company Updatefinance.yahoo.com - December 7 at 5:52 PMCytoDyn appoints Lalezari as its interim CEOmsn.com - November 22 at 12:19 AMCytoDyn Inc.: CytoDyn Appoints Jacob Lalezari M.D. as Interim CEOfinanznachrichten.de - November 21 at 9:14 AMCytoDyn Appoints Jacob Lalezari M.D. as Interim CEOfinance.yahoo.com - November 21 at 9:14 AMFormer biotech execs in 'brazen fraud' case want indictments dismissedbizjournals.com - September 21 at 11:57 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideAkebia Therapeutics Surges on FDA Approval for Anemia TreatmentApril 3, 2024 9:10 AMView Akebia Therapeutics Surges on FDA Approval for Anemia TreatmentAll Headlines Company DescriptionsAkebia TherapeuticsNASDAQ:AKBAAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Alder BiopharmaceuticalsNASDAQ:ALDRAlder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.BELLUS HealthOTCMKTS:BLUSFBELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.Constellation PharmaceuticalsNASDAQ:CNSTConstellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.CytoDynOTCMKTS:CYDYCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.